Vγ9Vδ2 T-cell receptor binding to phosphoantigen–butyrophilin 3A1 complex (Vγ9Vδ2 TCR–phosphoantigen–BTN3A1 complex)

The Vγ9Vδ2 T-cell receptor (TCR) binding to the phosphoantigen–butyrophilin 3A1 (BTN3A1) complex is a uniquely human immunological activation system. Vγ9Vδ2 T cells, a major γδ T cell subset in peripheral blood, are activated by small pyrophosphorylated metabolites called phosphoantigens (PAgs), which accumulate in infected or malignant cells. These PAgs bind to the intracellular B30.2 domain of BTN3A1, a type-I membrane protein structurally related to the B7 superfamily[1][4]. Upon PAg binding, BTN3A1 undergoes conformational changes and interacts with BTN2A1. This BTN3A1–BTN2A1 complex presents composite ligands to the Vγ9Vδ2 TCR, enabling T cell activation[2][3][4]. This mechanistic pathway endows Vγ9Vδ2 T cells with potent anti-tumor and anti-microbial functions and makes the complex a significant target for immunotherapeutic drug development[2][3][4][5]. Pharmacological agents such as zoledronate act indirectly by increasing endogenous PAg levels, thus promoting activation of this molecular complex[5]. Unresolved aspects include the precise molecular determinants for binding and the risk of non-specific immune activation with some therapeutic interventions[2][4][6]. The system serves both as a therapeutic target and as a functional biomarker in cancer and infection immunotherapy research.

Other names

Vγ9Vδ2 TCR–phosphoantigen–BTN3A1–BTN2A1 complexγδ TCR–phosphoantigen–BTN3A1 interactionVγ9Vδ2 TCR–BTN3A1 composite ligandVγ9Vδ2 T-cell receptor–phosphoantigen–BTN complex

Drugs (e.g., bisphosphonates) induce accumulation of endogenous phosphoantigens in target cells, promoting phosphoantigen binding to BTN3A1’s B30.2 domain, which enables complex formation with BTN2A1 and subsequent Vγ9Vδ2 TCR activation[4][5][3].